Castle Biosciences, Inc. Common Stock CG 46th Annual Growth Conference
Review the key takeaways and the transcript of this earnings call.
- Castle Biosciences reported a very strong second quarter driven by good performance in melanoma and Tissue Cypher tests, with modest incremental average selling price progress in the first half of the year.
- Melanoma test volume is expected to grow mid to high single digits in 2024, with about one third of estimated 130,000 invasive melanoma patients tested currently, and ongoing physician conversion.
- The Tissue Cypher test showed steady growth without clear seasonality, with approximately 15% patient penetration on a run rate basis, indicating significant room for growth in Barrett's esophagus surveillance.
- The advanced atopic dermatitis (AD) test was launched in Q4 2023, with around 1,000 orders in Q2 2024, showing good physician receptivity but still early in commercialization and reimbursement processes.
- The squamous cell carcinoma (SCC) test remains poorly reimbursed and not covered by Medicare, with the salesforce primarily focused on melanoma.
- Castle Biosciences expects to be adjusted EBITDA positive for the rest of 2024 and in 2027, with multiple products on the market and a robust pipeline of future opportunities.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Castle Biosciences. Castle offers a range of tests across dermatologic cancers and GI cancers as well, as well as atopic dermatitis, which we will talk about today. With the company, we have Frank Stokes, CFO. Thanks, Frank, for joining us today.
Sure. Appreciate it. So you had your second quarter results announced a couple of weeks ago.
A very strong quarter and guidance was adjusted. Can you just talk about what you saw in the quarter, the puts and takes, as well as the guidance update?
Yeah, sure. So two key drivers in the business are our DecisionDx-Melanoma and TissueCypher. We saw good performance in both. Modest, I would say, incremental ASP progress across both through the first half of the year. So I think the drivers there are continued penetration, continued physician conversion, and in both tests, really expanding the pool of a physician's patients that they want to test with those two tests. We raised our guidance a little bit more than the beat, so I think we see that signals some optimism in where things go in the second half and continued good performance on the whole franchise.
Okay. Specifically with melanoma, I think it was kind of an easier comp in the first quarter. Maybe it was not as great in the second. But what do you see as underlying growth trends in that business?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring